This effect adds to metabolic health, cellular health, and function
Additionally, semaglutide suppresses the release of glucagon, a hormone that elevates blood glucose levels
while, 7 (70%) cases in group 1 and 8 (88.9%) cases in group 2 were of mixed type (increase in epidermal melanization and melanophages in the papillary dermis with scattered melanin)
The FDA approved tirzepatide (Zepbound) for chronic weight management in November 2023, making it the second GLP-1 receptor agonist approved specifically for weight management following semaglutide's 2021 Wegovy approval
Kim Grundy, PT Author Kim Grundy is a physical therapist, as well as an experienced health and fitness writer that has been published in USA Today, SheKnows, Brides, Parents and more